TY -的T1 -新视Neuromyelitis复发急性严重程度量表(P5.249) JF -神经学乔-神经学六世- 84 - 14补充SP P5.249 AU -迈克尔·莱维首页盟莫林粉AU -斯文Jarius盟Friedemann保罗盟Orhan Aktas AU -西蒙Broadley AU - Philippe Cabre盟可能汉盟——阿奴雅各盟Gareth约翰AU -玛丽亚雷特盟罗曼Marignier AU -一郎中岛美嘉盟杰奎琳宫非盟-斯文Schippling AU -安东尼Traboulsee AU -布莱恩Weinshenker AU -迪恩Wingerchuk Y1 - 2015/04/06 UR - //www.ez-admanager.com/content/84/14_Supplement/P5.249.abstract N2 -目的:开发和验证一个客观的规模代表程度的神经功能障碍的急性复发Neuromyelitis视。背景:视Neuromyelitis(动)是一种自身免疫性疾病的中枢神经系统(CNS)不同于多发性硬化症(MS)。它的特点是反复发作的视神经炎(上)和纵向广泛的横向脊髓炎(LETM),这通常导致增量与事件相关的残疾。残疾通常被评为使用扩展残疾严重程度量表(eds)为女士开发试验。然而,eds视力和有限的变化不敏感的患者不能走路。DESIGN/METHODS: We designed a 34-point acute relapse severity scale specific to NMO, named the NMO Severity Scale (NMOSS) focusing on areas most significantly affected including 1) Visual Acuity, 2) Visual Fields, 3) Motor, 4) Sensory, 5) Bowel & Bladder, and 6) Brainstem Functions. We asked 17 international experts in NMO to review records from 20 acute NMO admissions to the Johns Hopkins Hospital to evaluate inter-rater reliability and accuracy of the NMOSS. RESULTS: The NMOSS is based on the EDSS but was modified to increase the sensitivity to visual acuity and visual fields. Motor, sensory and bowel/bladder scores were only slightly modified and the brainstem score was changed to focus on NMO-specific attacks of the area postrema and diencephalon. Validation of the NMOSS is ongoing; inter-rater reliability will be calculated using Spearman's rank correlation coefficient and the NMOSS will be analyzed for content and predictive validity. CONCLUSIONS: The NMOSS is a new NMO-specific disability scale for future clinical trials. Study Supported by: The Guthy Jackson Charitable FoundationDisclosure: Acorda Therapeutics; Sanofi; Viropharma, Inc.; NeuralStem, Inc.; Shire/Abvie; TerumoBCT Dr. Mealy has nothing to disclose. Dr. Jarius has received research support from Bayer Healthcare and Merck Serono. Dr. Paul has received personal compensation for activities with Teva Neuroscience, Sanofi-Aventis Pharmaceuticals, Bayer Schering Pharma, Merck Serono, Biogen Idec, MedImmune, and Novartis., Dr. Aktas has received personal compensation for activities with Bayer, Biogen Idec, Genzyme, Novartis, Teva Neuroscience, and Medimmune as an advisor. Dr. Broadley has nothing to disclose. Dr. Cabre has received personal compensation for activities with Biogen Idec, EMD Serono, and Novartis. Dr. Han has nothing to disclose. Dr. Jacob has nothing to disclose. Dr. John has received research support from Teva. Dr. Leite has nothing to disclose. Dr. Marignier has nothing to disclose. Dr. Nakashima has received personal compensation for activities with Bayer Schering Pharma, Novartis, and Biogen Idec. Dr. Nakashima has received research support from Mitsubishi Chemical Corporation. Dr. Palace has received personal compensation for activities with Novartis and Merck Serono. Dr. Schippling has received personal compensation for activities with Novartis. Dr. Schippling has received research support from Bayer Schering and Biogen Idec. Dr. Traboulsee has received personal compensation for activities with Roche Diagnostics Corporation, EMD Serono, Teva Neuroscience, and Biogen Idec, Novartis, and Genzyme Corporation. Dr. Weinshenker has received personal compensation for activities with Novartis, Biogen Idec, and Mitsubishi Pharmaceuticals, MedImmune Pharmaceuticals, Alexion Pharmaceuticals, Chugai Pharmaceutical, and Novartis. Dr. Weinshenker has received royalty pay Dr. Wingerchuk has received personal compensation for activities with Medimmune, Alexion, and Chugai. Dr. Wingerchuk has received research support from Alexion and TerumoBCT.Wednesday, April 22 2015, 2:00 pm-6:30 pm ER -